https://origin.rootz.global/api/company/ABBV| Name | Type | Description |
|---|---|---|
| Skyrizi (risankizumab) | service | IL-23 inhibitor biologic approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. |
| Rinvoq (upadacitinib) | service | Oral, once-daily selective JAK inhibitor approved for multiple inflammatory diseases including rheumatoid arthritis and atopic dermatitis. |
| Humira (adalimumab) | service | Biologic subcutaneous injection approved for numerous autoimmune diseases including rheumatoid arthritis and Crohn's disease. |
| Vraylar (cariprazine) | service | Dopamine D3/D2 receptor partial agonist indicated for schizophrenia, bipolar disorder, and major depressive disorder. |
| Botox Therapeutic (onabotulinumtoxinA) | service | Injectable neuromuscular blocking agent approved for chronic migraine, overactive bladder, spasticity, and other conditions. |
| Ubrelvy (ubrogepant) | service | CGRP receptor antagonist for acute treatment of migraine with or without aura in adults. |
| Qulipta (atogepant) | service | CGRP receptor antagonist for preventive treatment of episodic and chronic migraine in adults. |
| Vyalev (foscarbidopa and foslevodopa) | service | Subcutaneous 24-hour infusion therapy for motor fluctuations in adults with advanced Parkinson's disease. |
| Duodopa (carbidopa and levodopa) | service | Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease, marketed as Duopa in the United States. |
| Imbruvica (ibrutinib) | service | Oral BTK inhibitor approved for CLL, certain non-Hodgkin lymphomas, and chronic graft versus host disease. |
| Partner | Type | Description |
|---|---|---|
| GSK | licensing | GSK markets Botox Therapeutic in Japan on behalf of AbbVie. |
| Abbott Laboratories | strategic | Abbott distributed 100% of AbbVie's outstanding common stock to Abbott shareholders on January 1, 2013, making AbbVie independent. |
View all SEC EDGAR filings: EDGAR Company Page
Structured filing index: /api/company/ABBV/filings